Difference between revisions of "Mirtazapine-paroxetine"
From Psychiatrienet
| Line 7: | Line 7: | ||
| start = | | start = | ||
* '''Day 1:''' simultaneously start paroxetine in a normal dosage of 20 mg/day. | * '''Day 1:''' simultaneously start paroxetine in a normal dosage of 20 mg/day. | ||
| − | * '''Day 8:''' stop administration of mirtazapine and only continue administration of paroxetine. }} | + | * '''Day 8:''' stop administration of mirtazapine and only continue administration of paroxetine. |
| + | | info = | ||
| + | {{review}} | ||
| + | }} | ||
Revision as of 14:22, 7 October 2015
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from mirtazapine to paroxetine.[1] [2]
Stop mirtazapine - Before day 1: gradually reduce dosage of mirtazapine to a maximum of 30 mg/ day.
- Day 1: reduce a dosage of 30 mg/day to 15 mg/day.
Start paroxetine- Day 1: simultaneously start paroxetine in a normal dosage of 20 mg/day.
- Day 8: stop administration of mirtazapine and only continue administration of paroxetine.
More information- This switch is currently being reviewed.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
